iFAST Overview

  • Year Founded
  • 2022

Year Founded

  • Status
  • Private

  • Employees
  • 30

Employees

  • Latest Deal Type
  • Series A
  • (Upcoming)

  • Latest Deal Amount
  • $13.4M

  • Investors
  • 13

iFAST General Information

Description

Operator of a medical research company intended to reduce the threat of antimicrobial resistance. The company facilitates antimicrobial susceptibility test systems to avoid the growth of bacteria in the sample and determines the optimum antibiotic for clinicians to prescribe, enabling researchers to improve the outcomes.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Solent Business Park
  • 1500 Parkway, Whitley
  • Fareham PO15 7AF
  • England, United Kingdom
+44 07788
Primary Industry
Biotechnology
Other Industries
Other Healthcare Technology Systems
Corporate Office
  • Solent Business Park
  • 1500 Parkway, Whitley
  • Fareham PO15 7AF
  • England, United Kingdom
+44 07788

iFAST Timeline

20232024202520262027
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

iFAST Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Early Stage VC (Series A) 01-Jun-2027 $13.4M Upcoming Generating Revenue
6. Early Stage VC 27-May-2026 Completed Generating Revenue/Not Profitable
5. Seed Round 05-Nov-2024 Completed Product Development
4. Grant 25-Aug-2023 Completed Generating Revenue
3. Accelerator/Incubator 16-Mar-2023 Completed Startup
2. Seed Round 23-Jan-2023 $2.36M $2.36M Completed Startup
1. University Spin-Out 01-Apr-2022 Completed Startup
To view iFAST’s complete valuation and funding history, request access »

iFAST Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
SEED PREFERRED
SEED PREFERRED
Ordinary 104,994 $0.000013 $24.94 $24.94 1x $24.94 25.1%
To view iFAST’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

iFAST Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

iFAST Investors (13)

Investor Name Investor Type Holding Investor Since Participating Rounds
Einkaufsbüro Deutscher Eisenhändler Gesellschaft Mit Beschränkter Haftung Corporation Minority
OKG Capital Venture Capital Minority
Raw Ventures Venture Capital Minority
SHIFT Ventures (London) Venture Capital Minority
INCATE Accelerator/Incubator
You’re viewing 5 of 13 investors. Get the full list »

iFAST FAQs

  • When was iFAST founded?

    iFAST was founded in 2022.

  • Where is iFAST headquartered?

    iFAST is headquartered in Fareham, United Kingdom.

  • What is the size of iFAST?

    iFAST has 30 total employees.

  • What industry is iFAST in?

    iFAST’s primary industry is Biotechnology.

  • Is iFAST a private or public company?

    iFAST is a Private company.

  • What is iFAST’s current revenue?

    The current revenue for iFAST is .

  • How much funding has iFAST raised over time?

    iFAST has raised $15.6M.

  • Who are iFAST’s investors?

    Einkaufsbüro Deutscher Eisenhändler Gesellschaft Mit Beschränkter Haftung, OKG Capital, Raw Ventures, SHIFT Ventures (London), and INCATE are 5 of 13 investors who have invested in iFAST.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process